


CLINICAL ADVANCES FOR PEOPLE WITH LUPUS



A World Lupus Day Breakfast Panel Presentation

May 10, 2004

Hilton New York Hotel

AGENDA

Welcome and Introductions

Sandra C. Raymond, World Lupus Day Co-Chair
President and CEO, Lupus Foundation of America, Inc.

Panel Facilitator: Joan T. Merrill, M.D.
Medical Director, Lupus Foundation of America, Inc.

7:00

PRESTARA™ (prasterone) Clinical Trials Update: Prevention of Bone Mineral Density Loss in Women With Lupus

Genelabs Technologies, Inc.
Kenneth E. Schwartz, M.D., Vice President, Medical Affairs

7:10

Investigating LymphoStat-B™ Antibody: A Potential New Approach to SLE Treatment

Human Genome Sciences, Inc.
Marc R. Chevrier, MD, PhD, FACR, Associate Director, Clinical Research

7:15

Building on Recent CellCept® Data in Lupus

Aspreva Pharmaceuticals Corporation
Dr. Reinhard Baildon, Exec. VP Clinical & Regulatory Affairs

7:20

Early Clinical Experience of Abatacept in Treating Rheumatoid Arthritis

Bristol-Myers Squibb, Inc.
Jean-Claude Becker, MD, Medical Director

7:25

LJP 394 for the Treatment of Patients with Lupus Renal Disease

La Jolla Pharmaceutical, Inc.
Matthew D. Linnik, Ph.D., Chief Scientific Officer

7:30

Rituximab in SLE

Genentech, Inc.
Paul Brunetta, MD, Medical Director

7:35

Audience Question and Answer Period

7:40

Summary and Closing Remarks

Brian Hanner, World Lupus Day Co-Chair
Director, LUPUS UK

8:10

We are grateful for the generous, unrestricted support of these companies for this World Lupus Day program.

ASPREVA
PHARMACEUTICALS

biogen idec

Genentech
IN BUSINESS FOR LIFE

LA JOLLA
PHARMACEUTICAL COMPANY

GENELABS
TECHNOLOGIES, INC.

 **Bristol-Myers Squibb Company**

 **Human Genome Sciences**

 **WATSON Pharma, Inc.**
A Subsidiary of Watson Pharmaceuticals, Inc.